Effect of levodopa on healthy volunteers' facial emotion perception: An fMRI study

Clinical Neuropharmacology

Volumn 28, Issue 6, 2005, Pages 255-261

  Delaveau, Pauline ^a   Salgado Pineda, Pilar ^a   Wicker, Bruno ^a   Micallef Roll, Joëlle ^a   Blin, Olivier ^a,b  

^a CNRS   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

Dopaminergic system; Emotion processing; fMRI; Healthy volunteers

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; DOMPERIDONE; LEVODOPA; PLACEBO; DOPAMINE RECEPTOR STIMULATING AGENT; OXYGEN;

ADULT; AGED; AMYGDALOID NUCLEUS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG ACTIVITY; ELECTROENCEPHALOGRAPHY; EMOTION; FACIAL EXPRESSION; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MALE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERCEPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING; BLOOD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEMISPHERIC DOMINANCE; IMAGE PROCESSING; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; VASCULARIZATION;

AGED; AMYGDALA; CROSS-SECTIONAL STUDIES; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; EMOTIONS; FACIAL EXPRESSION; FEMALE; FUNCTIONAL LATERALITY; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LEVODOPA; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; OXYGEN;

EID: 33644875799     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000186651.96351.2e     Document Type: Article

References (49)

1. Salgado-Pineda P, Delaveau P, Blin O, et al. Dopaminergic contribution to regulation of emotional perception. Clin Neuropharmacol. 2005;28:228-237.
2. Oades RD, Halliday GM. Ventral tegmental (A10) system: neurobiology. 1. Anatomy and connectivity. Brain Res. 1987;434:117-165.
3. Adolph R. Neural systems for recognizing emotion. Curr Opin Neurobiol. 2002;12:169-177.
4. Breiter HC, Etcoff NL, Whalen PJ, et al. Response and habituation of the human amygdala during visual processing of facial expression. Neuron. 1996;17:875-887.
5. Yang TT, Menon V, Eliez S, et al. Amygdalar activation associated with positive and negative facial expressions. Neuroreport. 2002;13:1737-1741.
6. e édition américaine. Coquery JM, ed. Bruxelles: De Boeck Université; 2003.
7. O'Carroll E, Drysdale E, Cahill L, et al. Stimulation of the noradrenergic system enhances and blockade reduces memory for emotional in man. Psychol Med. 1999;29:1083-1088.
8. Fu CH, Williams SC, Cleare AJ, et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch Gen Psychiatry. 2004;61:877-889.
9. Harmer CJ, Shelley NC, Cowen PJ, et al. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry. 2004;161:1256-1263.
10. Grace AA, Rosenkranz JA. Regulation of conditioned responses of basolateral amygdala neurons. Physiol Behav. 2002;77:489-493.
11. Pezze MA, Feldon J. Mesolimbic dopaminergic pathways in fear conditioning. Prog Neurobiol. 2004;74:301-320.
12. Jacobs DH, Shuren J, Bowers D, et al. Emotional facial imagery, perception, and expression in Parkinson's disease. Neurology. 1995;45:1696-1702.
13. Dujardin K, Blairy S, Defebvre L, et al. Deficits in decoding emotional facial expressions in Parkinson's disease. Neuropsychologia. 2004;42:239-250.
14. Tessitore A, Hariri AR, Fera F, et al. Dopamine modulates the response of the human amygdala: a study in Parkinson's disease. J Neurosci. 2002;22:9099-9103.
15. Sprengelmeyer R, Young AW, Mahn K, et al. Facial expression recognition in people with medicated and unmedicated Parkinson's disease. Neuropsychologia. 2003;41:1047-1057.
16. Cools R, Barker RA, Sahakian BJ, et al. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex. 2001;11:1136-1143.
17. Lawrence AD, Calder AJ, McGowan SW, et al. Selective disruption of the recognition of facial expressions of anger. Neuroreport. 2002;13:881-884.
18. 2 receptor binding, mood, and attentiveness in humans: a replication study. Pharmacol Biochem Behav. 2003;74:425-432.
19. Gunning-Dixon FM, Gur RC, Perkins AC, et al. Age-related differences in brain activation during emotional face processing. Neurobiol Aging. 2003;24:285-295.
20. Paradiso S, Robinson RG, Andreasen NC, et al. Emotional activation of limbic circuitry in elderly normal subjects in a PET study. Am J Psychiatry. 1997;154:384-389.
21. Barili P, De Carolis G, Zaccheo D, et al. Sensitivity to ageing of the limbic dopaminergic system: a review. Mech Ageing Dev. 1998;106:57-92.
22. Folstein MF, Folstein SE, Mc Hugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res. 1975;12:189-198.
23. Nelson HE. A modified card sorting test sensitive to frontal lobe defects. Cortex. 1976;12:313-324.
24. Dougherty DM. IMT/DMT Immediate Memory Task & Delayed Memory Task: a research tool for studying attention and memory processes. Houston, TX: Neurobehavioral Research Laboratory and Clinic, University of Texas Health Science Center at Houston; 1999.
25. Benton AL. Manuel pour l'application du test de rétention visuelle: applications cliniques et expérimentales. [French]. Paris: Centre de Psychologie Appliquée; 1965.
26. Kaplan E, Goodglass H, Weintraub S. Boston Naming Test. Experimental edition. Boston: Aphasia Research Center, Boston University; 1976.
27. Wechsler D. MEM-III: Manuel de l'échelle clinique de mémoire. 3rd ed. Paris: Les Editions du Centre de Psychologie Appliquée; 2001.
28. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. In. Pichot P, ed. Psychological measurements in psychopharmacology: modern problem in pharmacopsychiatry. Paris: Karger, Basel, 1974:151-159.
29. Chana P, Fierro A, Reyes-Parada M, et al. Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbodopa 250/25 mg) in Parkinson's disease: a single dose study. Rev Med Chil. 2003;131:623-631.
30. Matsumoto D, Ekman P. Japanese and Caucasian facial expressions of emotion (JACFEE) and neutral faces (JACNeuF). Human Interaction Laboratory, University of California, San Francisco, California; 1988.
31. Brett M, Anton JL, Valabregue R, et al. Region of interest analysis using an SPM toolbox. Presented at the 8th International Conference on Functional Mapping of the Human Brain, Sendai, Japan, 2002. [Available in CD-ROM in NeuroImage 16, abstract 497.]
32. Talairach J, Tournoux P. Co-planar stereotaxic atlas of human brain. New York: Thieme; 1988.
33. Davidson RJ, Abercrombie H, Nitschke JB, et al. Regional brain function, emotion and disorders of emotion. Curr Opin Neurobiol. 1999;9:228-234.
34. Phan KL, Wager T, Taylor SF, et al. Functional neuroanatomy of emotion: a meta-analysis of emotion activation studies in PET and fMRI. Neuroimage. 2002;16:331-348.
35. Kosaka H, Omori M, Murata T, et al. Differential amygdala response during facial recognition in patients with schizophrenia: an fMRI study. Schizophr Res. 2002;57:87-95.
36. Crespo-Facorro B, Paradiso S, Andreasen NC, et al. Neural mechanisms of anhedonia in schizophrenia: a PET study of response to unpleasant and pleasant odors. JAMA. 2001;286:427-435.
37. Russell TA, Rubia K, Bullmore ET, et al. Exploring the social brain in schizophrenia: left prefrontal underactivation during mental attribution. Am J Psychiatry. 2000;157:2040-2042.
38. Schneider F, Weiss U, Kessler C, et al. Differential amygdala activation in schizophrenia during sadness. Schizophr Res. 1998;34:133-142.
39. Gur RE, McGrath C, Chan RM, et al. An fMRI study of facial emotion processing in patients with schizophrenia. Am J Psychiatry. 2002;159:1992-1999.
40. Johnston PJ, Katsikitis M, Carr VJ. A generalised deficit can account for problems in facial emotion recognition in schizophrenia. Biol Psychol. 2001;58:203-227.
41. Andreasen NC. Cognition and emotion in schizophrenia: neuroimaging approach. Encephale. 2002;28:S14-S15.
42. Paradiso S, Andreasen NC, Crespo-Facorro B, et al. Emotions in unmedicated patients with schizophrenia during evaluation with positron emission tomography. Am J Psychiatry. 2003;160:1775-1783.
43. Taylord SF, Liberzon I, Decker LR, et al. A functional anatomic study of emotion in schizophrenia. Schizophr Res. 2002;58:159-172.
44. Bullmore E, Suckling J, Zelaya F, et al. Practice and difficulty evoke anatomically and pharmacologically dissociable brain activation dynamics. Cereb Cortex. 2003;13:144-154.
45. Maruyama W, Naoi M, Narabayashi H. The metabolism of L-dopa and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients. J Neurol Sci. 1996;139:141-148.
46. Thorre K, Sarre S, Smolders I, et al. Dopaminergic regulation of serotonin release in the substantia nigra of the freely moving rat using microdialysis. Brain Res. 1998;15:107-116.
47. Rojahn J, Gerhards F, Matlock ST, et al. Reliability and validity studies of the facial discrimination task for emotion research. Psychiatry Res. 2000;95:169-181.
48. Kesler-West ML, Andersen AH, Smith CD, et al. Neural substrates of facial emotion processing using fMRI. Brain Res Cogn Brain Res. 2001;11:213-226.
49. Hariri AR, Mattay VS, Tessitore A, et al. Neocortical modulation of the amygdala response to fearful stimuli. Biol Psychiatry. 2003;53:494-501.